United Therapeutics Corporation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$103.8M
Doctors Paid
14,016
Transactions
100,837
2024 Total
$25.0M
Payment Breakdown by Category
Research$79.2M (76.3%)
Consulting$5.1M (4.9%)
Food & Beverage$2.3M (2.2%)
Travel$1.4M (1.3%)
Royalty/License$15,000 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $79.2M | 17,818 | 76.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10.1M | 7,593 | 9.8% |
| Consulting Fee | $5.1M | 1,868 | 4.9% |
| Education | $3.3M | 4,959 | 3.2% |
| Grant | $2.3M | 31 | 2.2% |
| Food and Beverage | $2.3M | 62,968 | 2.2% |
| Travel and Lodging | $1.4M | 5,585 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $93,155 | 13 | 0.1% |
| Royalty or License | $15,000 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,500 | 1 | 0.0% |
Payments by Type
Research
$79.2M
17,818 transactions
General
$24.6M
83,019 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | $15.8M | 16 | 3,208 |
| A MULTICENTER RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE | $5.9M | 4 | 1,434 |
| An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | $5.9M | 1 | 1,322 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDED TO PAH STANDARD OF CARE OR PAH-SPECIFIC BACKGROUND ORAL THERAPY IN SUBJECTS WITH WHO GROUP I PULMONARY HYPERTENSION | $5.5M | 8 | 1,500 |
| AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION DUE TO PARENCHYMAL LUNG DISEASE | $4.7M | 4 | 1,700 |
| A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) | $3.0M | 2 | 434 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH IN HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | $2.5M | 22 | 780 |
| Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | $2.3M | 4 | 530 |
| A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | $2.1M | 28 | 896 |
| SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN ADULT PH WITH ILD INCLUDING CPFE | $1.8M | 0 | 372 |
| A TWO-PART OPEN-LABEL RANDOMIZED PHASE IIIII STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER | $1.6M | 3 | 246 |
| EXPEDITE: A 16-WEEK MULTICENTER OPEN-LABEL STUDY OF REMODULIN INDUCTION FOLLOWED BY ORENITRAM OPTIMIZATION IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | $1.4M | 1 | 193 |
| A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | $1.4M | 0 | 527 |
| AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF - A LONG-TERM FOLLOW-UP TO STUDY TDE-HF-301 | $1.3M | 15 | 552 |
| ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | $1.3M | 11 | 945 |
| STUDY OF ORAL TREPROSTINL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION HFPEF | $1.2M | 0 | 135 |
| OPEN-LABEL EXTENSION STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION- A LONG-TERM FOLLOW-UP TO PROTOCOL TDE-PH-310 | $1.1M | 0 | 240 |
| INTRAVENOUS REMODULIN TREPROSTINIL AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN A RANDOMIZED PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY | $957,495 | 0 | 136 |
| AN OPEN LABEL EXTENSION STUDY TO EVALUATE INHALED TREPROSTINIL IN ADULT PH WITH ILD INCLUDING CPFE | $950,322 | 0 | 270 |
| A PHASE III INTERNATIONAL MULTI-CENTER RANDOMIZED DOUBLE- BLIND PLACEBO-CONTROLLED CLINICAL WORSENING STUDY OF UT-15C IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION RECEIVING BACKGROUND ORAL MONOTHERAPY | $757,631 | 1 | 184 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | $720,053 | 3 | 278 |
| Unspecified Research Projects | $639,405 | 2 | 14 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RALINEPAG TO EVALUATE SAFETY AND EFFECTS ON EXERCISE CAPACITY ASSESSED BY CPET IN SUBJECTS WITH WHO GROUP 1 PULMONARY HYPERTENSION WHO RECENTLY INITIATED THERAPY | $635,343 | 0 | 175 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION (PH) IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) | $523,499 | 0 | 169 |
| HUMAN MSC EXOSOME THERAPY FOR BPD INJURY IN THE PRETERM LAMB PRE-CLINICAL MODEL | $500,000 | 0 | 4 |
| REMODULIN AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN | $486,069 | 0 | 52 |
| UNSPECIFIED RESEARCH PROJECTS | $442,753 | 9 | 43 |
| Whole Genome Sequencing in PAH | $420,721 | 0 | 9 |
| A PHASE I STUDY OF 131I-MIBG WITH DINUTUXIMAB +/- VORINOSTAT FOR RELAPSED/REFRACTORY NEUROBLASTOMA | $408,186 | 0 | 15 |
| INTRAVENOUS REMODULIN (TREPROSTINIL) AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN: A RANDOMIZED PLACEBO-CONTROLLED SAFETY AND EFFICACY STUDY | $406,099 | 0 | 118 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Franck Rahaghi, M.d, M.D | Pulmonary Disease | Weston, FL | $558,217 | $0 |
| Lana Melendres-Groves, Md, MD | Internal Medicine | Albuquerque, NM | $546,230 | $0 |
| Hunter Champion, M.d, M.D | Cardiovascular Disease | Columbus, GA | $497,188 | $0 |
| Paul Forfia, Md, MD | Cardiovascular Disease | Philadelphia, PA | $414,502 | $0 |
| Robert Bourge, Md, MD | Cardiovascular Disease | Birmingham, AL | $395,820 | $0 |
| Ronald Oudiz, M.d, M.D | Cardiovascular Disease | Torrance, CA | $384,014 | $0 |
| Steven Nathan, Md, MD | Internal Medicine | Falls Church, VA | $381,242 | $0 |
| Dr. George Semeniuk, M.d, M.D | Hematology & Oncology | Newport Beach, CA | $353,940 | $0 |
| Ricardo Restrepo-Jaramillo, M.d, M.D | Internal Medicine | Tampa, FL | $316,753 | $0 |
| Dr. Jason Stienecker, D.o, D.O | Internal Medicine | Lima, OH | $304,643 | $0 |
| Abhijit Raval, Md, MD | Internal Medicine | Anderson, SC | $301,161 | $0 |
| Rajan Saggar, Md, MD | Pulmonary Disease | Los Angeles, CA | $241,262 | $0 |
| Dr. John Ryan, Mbbchbao, MBBCHBAO | Cardiovascular Disease | Salt Lake City, UT | $221,381 | $0 |
| Jimmy Smith, D.o, D.O | Critical Care Medicine | Lexington, KY | $214,803 | $0 |
| Anjali Vaidya, Md, MD | Cardiovascular Disease | Philadelphia, PA | $214,348 | $0 |
| Dr. Abubakr Bajwa, M.d, M.D | Pulmonary Disease | Jacksonville, FL | $211,972 | $0 |
| Vallerie Mclaughlin, Md, MD | Internal Medicine | Ann Arbor, MI | $201,288 | $0 |
| Jorge Mallea, Md, MD | Pulmonary Disease | Jacksonville, FL | $201,245 | $0 |
| Unknown Provider | — | — | $196,289 | $0 |
| Oksana Shlobin, Md, MD | Pulmonary Disease | Falls Church, VA | $194,960 | $0 |
| Dr. Anthony Cucci, Md, MD | Critical Care Medicine | Akron, OH | $183,921 | $0 |
| Kristin Highland, M.d, M.D | Rheumatology | Cleveland, OH | $178,736 | $0 |
| Michael Cuttica, Md, MD | Critical Care Medicine | Chicago, IL | $176,979 | $0 |
| Dr. Muhyaldeen Dia, Md,Facc, MD,FACC | Cardiovascular Disease | Oak Lawn, IL | $173,325 | $0 |
| Dr. Alvaro Aranda- Rodriguez, Md, MD | Pulmonary Disease | Guaynabo, PR | $167,447 | $0 |
About United Therapeutics Corporation
United Therapeutics Corporation has made $103.8M in payments to 14,016 healthcare providers, recorded across 100,837 transactions in the CMS Open Payments database. In 2024, the company paid $25.0M. The top product by payment volume is TYVASO ($42.6M).
Payments were distributed across 165 medical specialties. The top specialty by payment amount is Internal Medicine ($4.5M to 2,585 doctors).
Payment categories include: Food & Beverage ($2.3M), Consulting ($5.1M), Research ($79.2M), Travel & Lodging ($1.4M), Royalties ($15,000).
United Therapeutics Corporation is associated with 6 products in the CMS Open Payments database, including TYVASO, ORENITRAM, and REMODULIN.